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Amino Acid Variation in HLA Class II Proteins
Is a Major Determinant of Humoral Response
to Common Viruses
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The magnitude of the human antibody response to viral antigens is highly variable. To explore the human genetic contribution to this
variability, we performed genome-wide association studies of the immunoglobulin G response to 14 pathogenic viruses in 2,363 immu-
nocompetent adults. Significant associations were observed in the major histocompatibility complex region on chromosome 6 for influ-
enza A virus, Epstein-Barr virus, JC polyomavirus, andMerkel cell polyomavirus. Using local imputation and finemapping, we identified
specific amino acid residues in human leucocyte antigen (HLA) class II proteins as the most probable causal variants underlying these
association signals. Common HLA-DRb1 haplotypes showed virus-specific patterns of humoral-response regulation. We observed an
overlap between variants affecting the humoral response to influenza A and EBV and variants previously associated with autoimmune
diseases related to these viruses. The results of this study emphasize the central and pathogen-specific role of HLA class II variation in the
modulation of humoral immune response to viral antigens in humans.The humoral immune response plays an essential role in
the control and prevention of viral infections in humans.
It has long been known that concentrations of serum im-
munoglobulins vary from person to person,1 and antibody
titers against prevalent viruses have been shown to be
highly variable in the population.2,3 A significant fraction
of that variation is heritable,1,3 yet little is known about
the human genetic control and regulation of the immuno-
globulin response to specific pathogens.
To investigate the impact of common human genetic
variation on humoral immunity and to identify path-
ogen-specific variants associated with antibody response,
wemeasured serum immunoglobulinG (IgG) levels against
14 common viruses (Table 1) in 2,363 immunocompetent
adults of European ancestry (Figure S1) with available
genome-wide genotype data,4 comprising 1,147 anony-
mized blood donors (62.0% male, mean age 5 SD ¼
37.5 5 13.2) and 1,216 individuals with psychiatric diag-
noses (64.9% male, mean age 5 SD ¼ 40.6 5 13.5) who
were recruited for the Go¨ttingen Research Association for
Schizophrenia (GRAS).5,6 All study participants provided
informed consent, including consent for genetic testing,
and the GRAS data collection has been approved by the
ethical committee of the Georg-August-Universita¨t Go¨ttin-
gen aswell as by the respective local regulatories and ethical
committees of all collaborating centers.6 All subject data
were collected in accordance with ethical guidelines and
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of IgG levels is provided in Table S1. We used multiplex
serology on the Luminex platform, based on glutathione
S-transferase (GST) fusion capture immunosorbent assays
combined with fluorescent-bead technology,8 or commer-
cially available ELISA-based Enzygnost or Novagnost as-
says (Siemens Healthcare Diagnostics). The latter were
automatically processed on the BEP III System (Siemens
Healthcare Diagnostics) and interpreted (according to the
manufacturer’s instructions) as positive, negative, or
borderline (the latter of was defined as negative for the pur-
pose of statistics). For the Luminex-based assays, seronega-
tivity was defined as the absence of detectable IgG.
Genome-wide SNP genotyping was performed with an
Axiom myDesign genotyping array (Affymetrix) and was
subject to stringent quality control steps as described previ-
ously.4 Imputation of unobserved genotypes was per-
formed with the 1000 Genomes Project phase 1 v.3
haplotypes as a reference panel. Genotypes were pre-
phased with MaCH v.19 and subsequently imputed by
Minimac.10 SNPs with a reported r2 quality metric
score < 0.8 or a minor allele frequency (MAF) < 5%, as
well as reported markers on sex chromosomes, were
excluded from downstream analyses. SNPs were also
filtered on the basis of ‘‘missingness’’ (excluded if they
had < 95% genotyping rate) and marked deviation from
the Hardy-Weinberg equilibrium (excluded if p < 5 3
107). We then used logistic or linear regression modelsausanne, Switzerland; 2Swiss Institute of Bioinformatics, 1015 Lausanne,
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Table 1. List of Analyzed Viruses and Seroprevalence
Family Species Name of Test or Epitope N Seropositive (%) IgG Levelsa
Herpesviridae cytomegalovirus P28 1,065 (45.1) 8.0 5 1.1
P150 1,049 (44.4) 7.9 5 1.0
Epstein-Barr virus EBNA 2,162 (91.5) 8.9 5 0.5
herpes simplex virus-1 Novagnost HSV1 IgG 1,473 (62.3) 10.4 5 0.4
varizella zoster virus Enzygnost Anti-VZV/IgG 2,304 (97.5) 13.7 5 0.6
Orthomyxoviridae influenza A virus Novagnost Influenza A IgG 1,594 (67.5) 10.0 5 0.4
influenza B virus Novagnost Influenza B IgG 497 (21.0) 9.5 5 0.2
Paramyxoviridae measles virus Enzygnost Anti-Measles Virus/IgG 2,177 (92.1) 15.1 5 0.9
mumps virus Enzygnost Anti-Parotitis Virus/IgG 1,862 (78.8) 14.6 5 0.7
Parvoviridae parvovirus B19 Novagnost Parvovirus B 19 IgG 1,664 (70.4) 10.9 5 0.4
Polyomaviridae BK polyomavirus VP1 2,226 (94.2) 8.4 5 1.0
JC polyomavirus VP1 1,268 (53.7) 7.1 5 0.8
Merkel cell polyomavirus VP1 1,871 (79.2) 8.0 5 1.0
trichodysplasia spinulosa-associated
polyomavirus
VP1 2,020 (85.5) 8.9 5 1.1
Togaviridae rubella virus Enzygnost Anti-Rubella Virus/IgG 2,216 (93.8) 11.4 5 0.9
aLog normalized, mean 5 SD.in PLINK v.1.911 to test for association between ~six
million SNPs and IgG response to 14 common human vi-
ruses (Table 1), using both a case-control study design
(serostatus: antibody positive versus negative) and a
continuous, quantitative approach (log-normalized IgG
levels in seropositive samples). The first three principal
components, calculated with GCTA (v.1.24),12 as well as
sex and age, which affect humoral response phenotypes
(Table S2), were included as covariates in all analyses. In
case of significant differences in serostatus or IgG levels be-
tween healthy control individuals and individuals affected
by neuropsychiatric disease (Table S3), psychiatric diag-
nosis was included as an additional binary covariate. WeTable 2. Summary of Genome-Wide Significant Association Results
Study Design: Serostatu
Influenza A JC
SNP ID (coded allele) rs140012631 (C) rs9
p value 1.06 3 1014 8.8
OR or betaa (95% CI) 2.02 (1.84,2.19) 1.7
Classical HLA allele Allele HLA-DQB1*05:01 HL
p value 4.91 3 1012 4.1
OR or betaa (95% CI) 0.53 (0.44,0.63) 0.6
Amino acid Protein (position) HLA-DRb1 (96) HL
Omnibus p value 2.64 3 1016 1.2
The strongest associated GWAS SNP, classical HLA allele, and amino acid positio
p values and effect estimates. OR, odds ratio; CI, confidence interval.
aOR is shown for the serostatus study design, and beta is shown for the IgG level
The Americanobserved no evidence of residual inflation in any test statis-
tic (l ¼ 0.99–1.04, Figure S2).
Correcting for the number of SNPs and viruses tested,
we observed genome-wide significant signals (p < 3.57 3
109) in the human leucocyte antigen (HLA) class II region
of the major histocompatibility complex (MHC) on chro-
mosome 6 for influenza A virus, Epstein-Barr virus (EBV),
JC polyomavirus (JCPyV), and Merkel cell polyomavirus
(MCPyV) (Table 2, Figure S3). Full summary association re-
sults are available for download from Zenodo.
To fine map the associated region and pinpoint poten-
tially functional variants, we imputed four-digit classical
HLA alleles and variable amino acid positions in the HLAs Study Design: IgG Levels
PyV MCPyV EBV
269910 (A) rs9269268 (C) rs6927022 (A)
8 3 1012 2.67 3 1010 7.35 3 1026
4 (1.58,1.90) 1.53 (1.40,1.66) 0.16 (0.13,0.19)
A-DQA1*01:02 HLA-DQB1*06:02 HLA-DRB1*07:01
1 3 109 1.35 3 109 1.01 3 1014
5 (0.56,0.75) 0.56 (0.46,0.67) 0.17 (0.21,0.12)
A-DRb1 (133) HLA-DRb1 (13) HLA-DRb1 (11)
7 3 1011 1.87 3 1010 5.85 3 1023
n for each genome-wide significant virus is shown, along with corresponding
s study design.
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Figure 1. Effect of Common HLA-DRb1
Haplotypes on Virus Serostatus or Anti-
body Levels
(A) Estimated effects for HLA-DRb1 haplo-
types as defined by the strongest associated
amino acid positions for influenza A virus,
JCPyV, and MCPyV serostatus, as well as
EBV IgG levels (Table 2). These four posi-
tions were imputed with SNP2HLA and all
showed an imputation accuracy of > 99%
in the original publication.13 The Val-His-
Tyr-Arg-encoding haplotype with a fre-
quency of 14.9%, present in classical HLA
alleles HLA-DRB1*04:01 and HLA-DRB1*
04:04, was chosen as reference (i.e., given
an OR of 1, or a beta of 0, respectively)
and not included in the figure. Only
common haplotypes with a frequency
of > 10% were included in the analysis
and accounted for 93.1% of haplotype
diversity. Diamonds designate estimated
effect sizes; error bars define the 95% confi-
dence interval. OR, odds ratio
(B) 3D model of the HLA-DR ab hetero-
dimer. The protein is shown in front (left)
and side (right) views. The DR a chain
is displayed in gray and the b chain in
green. Associated amino acid positions, as
selected for haplotype analysis, are high-
lighted. This figure was prepared with
UCSF chimera,14 with Protein Data Bank
code PDB: 4MCY.15class I and II proteins by using SNP2HLA and the T1DGC
Immunochip/HLA reference panel13 and tested these for
association with IgG response (Tables S4 and S5). 101
HLA alleles and 200 amino acids had a MAF > 1% and
were included in the analysis (r2 quality metric score:
median ¼ 0.99, interquartile range ¼ 0.98–1), and we
used a multi-degree-of-freedom omnibus test to test for as-
sociation atmulti-allelic amino acid positions with three or
more possible states. For all viruses with genome-wide sig-
nificant SNPs, we found corresponding associations with
HLA class II alleles and amino acids (Table 2), and they ex-
plained most of the SNP association signals when included
as covariates in conditional analyses (Table S6). The
residual SNP significance observed in some of the condi-
tional analyses suggests the existence of additional
associated alleles or amino acids that did not reach
genome-wide significance, although non-classical MHC
associations or HLA imputation errors could also play a
role. Among imputed amino acids, the strongest associa-
tions were observed for positions in HLA-DRb1 (Table 2,
Table S5). We therefore analyzed the potential impact of
common HLA-DRb1 haplotypes on IgG response to
influenza A, EBV, JCPyV, and MCPyV (Figure 1). This anal-
ysis showed no consistency in the associations: the size
and directionality of the effects were virus specific
(Figure 1A). Most prominently, the amino acid haplotypes
present in the classical alleles HLA-DRB1*15:01 or HLA-
DRB1*16:01 were associated with influenza A seroposi-
tivity and higher anti-EBV IgG levels, but with JCPyV740 The American Journal of Human Genetics 97, 738–743, Novemband MCPyV seronegativity. In contrast, the haplotype pre-
sent in HLA-DRB1*01:01 were associated with MCPyV
seropositivity and higher anti-EBV IgG levels, but with
influenza A seronegativity.
We next explored the virus-specific associations in more
detail. Anti-influenza A IgG antibodies were detected in
approximately two thirds of study participants (Table 1),
and two SNPs mapping to the HLA-DRB1 (MIM: 142857),
DQA1 (MIM: 146880), and DQB1 (MIM: 604305) gene re-
gions were identified as independently associated with
influenza A seropositivity in the genome-wide SNP screen
(Figure 2A). Amino acid position 96 in HLA-DRb1 was
associated more strongly with influenza A serostatus
than any SNP or classical HLA allele (omnibus p ¼ 2.6 3
1016, Table 2) and explained most of the association sig-
nals of both independently associated SNPs when included
in a conditional analysis. The residual significance of
p ¼ 9.5 3 104 for rs140012631 and p ¼ 1.0 3 104 for
rs9269912 might, however, imply that these SNPs tag
additional classical or non-classical HLA effects that did
not reach our significance threshold. Individuals carrying
a glutamine at position 96 were more likely to have detect-
able levels of anti-influenza A IgG (odds ratio [OR] ¼ 1.68),
whereas the presence of a glutamic acid was associated
with seronegativity (OR ¼ 0.51, Figure 2B). These two
amino acids are carried by the HLA-DRB1*15:01 and the
HLA-DRB1*01:01 alleles, respectively. They are in almost
perfect linkage disequilibrium (LD) with HLA-DQB1*
06:02 andHLA-DQB1*05:01, respectively (Table S7), whicher 5, 2015
Figure 2. GWAS and HLA association results for influenza A
serostatus
(A) Regional association plot of GWAS results. Values of –log10(p)
are plotted by their position in the MHC genomic region on chro-
mosome 6. The most significant association was observed for
rs140012631 (p ¼ 1.1 3 1014, OR ¼ 2.01 for the C allele). Ac-
counting for the effect of rs140012631, we observed an indepen-
dent association at rs9269912 (p ¼ 8.5 3 1010, OR ¼ 0.57 for
the T allele). A further step of forward conditioning left no
genome-wide significant signal. The dashed horizontal line indi-
cates the threshold for genome-wide significance (p ¼ 3.57 3
109). The annotated dashed vertical lines indicate the positions
of the classical HLA genes.
(B) Effect estimates for amino acid residues at position 96 of HLA-
DRb1 (omnibus p ¼ 2.6 3 1016). Designated classical HLA alleles
contain the respective amino acid residue at the given position.
OR, odds ratio; CI, confidence interval.
(C) Association results and conditional regression for classical HLA
alleles. Conditioning on HLA-DQB1*05:01 did not reveal further
independent associations (threshold: p ¼ 3.57 3 109). PC, prin-
cipal component; OR, odds ratio; CI, confidence interval.were the most strongly associated classical HLA alleles
(Figure 2C). This result is consistent with a recent study
associating HLA-DRB1*15:01 with increased responsive-
ness to trivalent influenza vaccines in Hispanic chil-
dren.16 Interestingly, the HLA-DRB1*15:01-HLA-DQB1*
06:02 haplotype is found in nearly 100% of individuals
with narcolepsy (MIM: 161400),17,18 a condition with
strong evidence for an autoimmune basis and with a
possible, but still controversial, mechanistic link to
influenza infection.19,20 The same HLA class II haplotype
has also been shown to be positively associated with
multiple sclerosis (MIM: 126200),21 systemic lupus erythe-
matosus (MIM: 152700),22,23 and Goodpasture disease
(MIM: 233450).24
More than 90% of study participants had detectable IgG
against the EBV-encoded nuclear antigen-1 (EBNA-1), an
antigen expressed in both latent and lytic modes of infec-
tion and that is essential for efficient EBV genome replica-
tion, persistence, and transcription in dividing cells. A
large number of HLA SNPs were significantly associated
with anti-EBNA-1 IgG levels (Figure S4A), consistent withThe Americanthe results of a previous study.25 Among amino acids, posi-
tions 11 and 26 of HLA-DRb1 showed strong, independent
associations (Table 2, Figure S4B), which together ex-
plained the top SNP association from the genome-wide as-
sociation studies (GWASs) (conditional p ¼ 0.04, Table S6).
Among classical alleles, HLA-DRB1*07:01 showed the
strongest association result (Figure S4C), and there was
an independent association ofHLA-DRB1*03:01. However,
these two alleles could not completely explain the top
GWAS hit (residual p ¼ 2.6 3 1011, Table S6), pointing
to a possible relevance of additional classical HLA alleles
that did not reach the significance threshold in our study.
EBV is known or suspected to play a role in multiple scle-
rosis26 and systemic autoimmune diseases,27 and we
observed an overlap between the genetic determinants of
IgG response to EBV and the HLA class II variants that
have been reported to associate with autoimmunity. Car-
riage of a glycine at HLA-DRb1 position 11 was associated
with decreased antibody levels (Figure S4B) and a lower
risk of seropositive28 and seronegative29 rheumatoid
arthritis (MIM: 180300). On the contrary, IgG levels were
higher in individuals carrying a proline at position 11
(Figure S4B), which is in strong LD with alanine at position
71 (r2¼ 0.83, Table S8) and carried by theHLA-DRB1*15:01
classical allele. HLA-DRb1 position 71 and HLA-DRB1*
15:01 have been reported as the strongest genetic risk fac-
tors for multiple sclerosis at the level of amino acids and
classical HLA alleles, respectively.21 However, the direc-
tionality of immune response and autoimmune disease
risk associations is not always consistent, and larger study
cohorts will be required to determine the role and extent of
the contribution of EBV immune response to autoimmune
disease susceptibility.
We also observed significant SNP associations in the HLA
class II region for JCPyV and MCPyV serostatus and for
MCPyV IgG levels (Table 2, Figures S5A, S6A, and S7).
HLA-DRb1 positions 133 and 13 showed the strongest
amino acid associations with JCPyV and MCPyV serosta-
tus, respectively (Figures S5B and S6B), whereas HLA-
DQA1*01:02 and HLA-DQB1*06:02 were associated with
JCPyV and MCPyV seronegativity, respectively (Figures
S5C and S6C). These two alleles are in strong LD with
HLA-DRB1*15:01 (Table S7), which was found to be associ-
ated with JCPyV seronegativity previously.30 No classical
HLA alleles or amino acids reached the significance
threshold for MCPyV IgG levels.
Genome-wide significant HLA class II amino acids ex-
plained between 2.5% (JCPyV serostatus) and 5.4% (EBV
anti-EBNA-1 IgG levels) of the phenotypic variance (Table
S9). With our sample size, we had > 80% power to detect
variants with a MAF of 10% that (1) explain at least 2.5%
of the trait variance (IgG levels) in the case of 80% seropos-
itivity or (2) have an OR of 1.5 for a discrete trait with 67%
seropositivity.31
Although the continuous phenotype—IgG levels in sero-
positive individuals—is a direct indicator of the intensity
of the humoral immune response, the interpretationJournal of Human Genetics 97, 738–743, November 5, 2015 741
of the dichotomous phenotype—serostatus—is not as
straightforward. Seronegativity can indeed reflect both
non-exposure and IgG levels under the detection limit. A
correlation analysis of ORs of the dichotomous trait and
the respective betas of the continuous trait showed highly
significant results (Table S10), suggesting that seronega-
tivity results from very low IgG levels rather than from
lack of exposure in a subset of the study population.
Thus, we sought to maximize power by using the largest
possible sample (i.e., by including seronegative individuals
in the dichotomous analyses), particularly for viruses with
a large seronegative fraction.
In summary, we here present a cross-pathogen, genome-
wide investigationof the roleofhost genetics inmodulating
the individual IgG response to common viral antigens. We
identified a strong association between HLA class II varia-
tion, in particular HLA-DRb1 amino acid variants, and IgG
response to several prevalent viruses. Our study illustrates
the value of GWASs in infectious disease research and em-
phasizes the importance of fine mapping SNP association
signals in theMHCvia imputationof potentially functional
HLA variation; doing so offers the unique possibility for a
straightforward investigation of putative causal variants.13
The pathogen-specific patterns of association that we
observed suggest that small differences in the capacity of
HLA-DRb1 proteins to bind specific viral peptides and pre-
sent them efficiently to CD4þ Tcells can have ameasurable
impact on downstream antibody production. The concor-
dance in associated genetic loci between IgG response to
several common viral antigens and antibody-dependent
autoimmune diseases observed in this study is intriguing.
Although our results do not allow for the conclusion of a
direct causative role of these viruses in autoimmune patho-
genesis, they strongly encourage further genetic and func-
tional work. Understanding how genetic differences affect
human response to infection might ultimately inform
drug and vaccine development and facilitate personalized
preventive and therapeutic approaches.Supplemental Data
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